Picture of Atea Pharmaceuticals logo

AVIR — Atea Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Atea Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

* Atea Pharmaceuticals Inc  AVIR.OQ  reported a quarterly
adjusted
loss of 10 cents​​ per share for the quarter ended in September.
The mean expectation of four analysts for the quarter was for a
loss of 44 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Atea Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 10 cents​.
    * The mean earnings estimate of analysts had risen by
about 8.9%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Atea Pharmaceuticals Inc shares had risen by 6.2% this
quarter and lost 32.4% so far this year.
    * The company reported a quarterly loss of $8.07 million.
    * Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $8.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
7 at 10:58 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.44          -0.10          Beat
 Jun. 30 2022      -0.52          -0.38          Beat
 Mar. 31 2022      -0.58          -0.51          Beat
 Dec. 31 2021      0.17           1.34           Beat

Recent news on Atea Pharmaceuticals

See all news